Loading patent…
AssigneeSynerkine Pharma B.V.
InventorsJoel Adrianus Gijsbert Van Roon, Sarita Aimee Yvonne Hartgring, Cornelis Erik Hack, Christina Louws, Floris Paulus Jacobus Gerardus Lafeber
Estimating the term…
The invention is concerned with a fusion protein comprising interleukin 10 and interleukin 4, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of osteoarthritis, chronic pain, a condition characterized by local or systemic inflammation, immune activation, and/or lymphoproliferation.
A method of treating chronic pain, local inflammation, or systemic inflammation, comprising administering to a human patient in need thereof an effective amount of a pharmaceutical composition that comprises:(a) a fusion protein consisting of, from N- to C-terminal, a human IL-4, a linker, and a human IL-10;
A method of treating chronic pain, local inflammation, or systemic inflammation, comprising administering to a human patient in need thereof an effective amount of a fusion protein that comprises IL-4 and IL-10, wherein the fusion protein comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO:
Dependencies are inferred from the claim text.